In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count <200×109/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p<0.001). Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results.
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis / Palandri, Francesca; Palumbo, Giuseppe Alberto; Bonifacio, Massimiliano; Tiribelli, Mario; Benevolo, Giulia; Martino, Bruno; Abruzzese, Elisabetta; D'Adda, Mariella; Polverelli, Nicola; Bergamaschi, Micaela; Tieghi, Alessia; Cavazzini, Francesco; Ibatici, Adalberto; Crugnola, Monica; Bosi, Costanza; Latagliata, Roberto; Di Veroli, Ambra; Scaffidi, Luigi; de Marchi, Federico; Cerqui, Elisa; Anaclerico, Barbara; De Matteis, Giovanna; Spinsanti, Marco; Sabattini, Elena; Catani, Lucia; Aversa, Franco; Di Raimondo, Francesco; Vitolo, Umberto; Lemoli, Roberto Massimo; Fanin, Renato; Merli, Francesco; Russo, Domenico; Cuneo, Antonio; Bacchi Reggiani, Maria Letizia; Cavo, Michele; Vianelli, Nicola; Breccia, Massimo. - In: ONCOTARGET. - ISSN 1949-2553. - STAMPA. - 8:45(2017), pp. 79073-79086. [10.18632/oncotarget.18674]
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Palandri, Francesca;Polverelli, Nicola;Spinsanti, Marco;Sabattini, Elena;Catani, Lucia;Lemoli, Roberto Massimo;Russo, Domenico;Cuneo, Antonio;Bacchi Reggiani, Maria Letizia;Cavo, Michele;Vianelli, Nicola;
2017
Abstract
In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count <200×109/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p<0.001). Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.